{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=8", "query": { "intervention": "fludarabine", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 1451, "total_pages": 146, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fludarabine&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T04:28:30.239Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04223765", "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mantle Cell Lymphoma", "Follicular Lymphoma", "Splenic Marginal Zone Lymphoma", "Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "Nodal Marginal Zone Lymphoma", "Indolent Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CAR.k.28", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-11-12", "completion_date": "2043-03-22", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04223765" }, { "nct_id": "NCT05950334", "title": "FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory B-Cell Lymphoma" ], "interventions": [ { "name": "FT522", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-11-16", "completion_date": "2025-06-30", "has_results": false, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 7, "location_summary": "Orlando, Florida • Detroit, Michigan • Minneapolis, Minnesota + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05950334" }, { "nct_id": "NCT03333486", "title": "Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Leukemia in Remission", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia With FLT3/ITD Mutation", "Acute Myeloid Leukemia With Gene Mutations", "Aplastic Anemia", "B-Cell Non-Hodgkin Lymphoma", "CD40 Ligand Deficiency", "Chronic Granulomatous Disease", "Chronic Leukemia in Remission", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Congenital Amegakaryocytic Thrombocytopenia", "Congenital Neutropenia", "Congenital Pure Red Cell Aplasia", "Glanzmann Thrombasthenia", "Immunodeficiency Syndrome", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Plasma Cell Myeloma", "Polycythemia Vera", "Recurrent Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndrome", "Severe Aplastic Anemia", "Shwachman-Diamond Syndrome", "Sickle Cell Disease", "T-Cell Non-Hodgkin Lymphoma", "Thalassemia", "Waldenstrom Macroglobulinemia", "Wiskott-Aldrich Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "75 Years", "sex": "ALL", "summary": "1 Year to 75 Years" }, "enrollment_count": 31, "start_date": "2017-12-07", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333486" }, { "nct_id": "NCT00005803", "title": "Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prolymphocytic Leukemia", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Childhood Hodgkin Lymphoma", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Small Lymphocytic Lymphoma", "T-Cell Chronic Lymphocytic Leukemia", "T-Cell Prolymphocytic Leukemia" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Therapeutic Autologous Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 76, "start_date": "1999-09", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 4, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005803" }, { "nct_id": "NCT01773395", "title": "GVAX vs. Placebo for MDS/AML After Allo HSCT", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia" ], "interventions": [ { "name": "GVAX", "type": "BIOLOGICAL" }, { "name": "Placebo Vaccine", "type": "BIOLOGICAL" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2013-01-08", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2022-07-18", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01773395" }, { "nct_id": "NCT06500273", "title": "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B-cell Lymphoma" ], "interventions": [ { "name": "cemacabtagene ansegedleucel", "type": "GENETIC" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™", "type": "DEVICE" } ], "intervention_types": [ "GENETIC", "DRUG", "DEVICE" ], "sponsor": "Allogene Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2024-06-18", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 63, "location_summary": "Gilbert, Arizona • Hot Springs, Arkansas • Berkeley, California + 51 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06500273" }, { "nct_id": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Richter Syndrome" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-06-02", "completion_date": "2027-08-24", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672173" }, { "nct_id": "NCT00006379", "title": "Non-Ablative Allo HSCT For Hematologic Malignancies or SAA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Precancerous/Nonmalignant Condition", "Small Intestine Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "graft-versus-tumor induction therapy", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 58, "start_date": "2000-06", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-12-08", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006379" }, { "nct_id": "NCT03240861", "title": "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HLA-A*0201 Positive Cells Present", "Locally Advanced Malignant Neoplasm", "NY-ESO-1 Positive", "Unresectable Malignant Neoplasm", "Sarcoma" ], "interventions": [ { "name": "18F-FHBG", "type": "OTHER" }, { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Cellular Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 5, "start_date": "2017-07-26", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03240861" }, { "nct_id": "NCT07875413", "title": "Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Large B Cell Lymphoma", "LBCL", "Diffuse Large B Cell Lymphoma (DLBCL)", "Relapse Diffuse Large B Cell Lymphoma", "High Grade B Cell Lymphoma", "FL", "HGBL", "Transformed Follicular Lymphoma (TFL)", "Primary Mediastinal B Cell Lymphoma", "PMBCL", "HGBL With MYC and BCL2 and/or BCL6 Rearrangements" ], "interventions": [ { "name": "Prizloncabtagene Autoleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AbelZeta Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2027-05", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-25T04:28:30.239Z", "location_count": 2, "location_summary": "Gilbert, Arizona • La Jolla, California", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07875413" } ] }